Axsome Completes Patient Enrollment in Phase 2 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics Inc has completed of patient enrollment in the CONCERT study, a Phase 2, randomized, double-blind, placebo-controlled, crossover, trial of AXS-12 in patients with narcolepsy. AXS-12 (reboxetine) is a novel,...
Read More